首页> 外文期刊>Anesthesiology >Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats.
【24h】

Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats.

机译:重新配制的微乳丙泊酚在大鼠中的理化性质,药代动力学和药效学。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: A newly developed microemulsion propofol consisted of 10% purified poloxamer 188 and 0.7% polyethylene glycol 660 hydroxystearate. The authors studied the physicochemical properties, aqueous free propofol concentration, and plasma bradykinin generation. Pharmacokinetics and pharmacodynamics were also evaluated in rats. METHODS: The pH, particle size, and osmolarity of microemulsion propofol were measured using a pH meter, particle size analyzer, and cryoscopic osmometer, respectively. The aqueous free propofol and plasma bradykinin were measured by a dialysis method and radioimmunoassay, respectively. Microemulsion propofol was administered by zero-order infusion of 0.5, 1.0, and 1.5 mg . kg . min for 20 min in 30 rats. The electroencephalographic approximate entropy was used as a surrogate measure of propofol effect. RESULTS: The pH, osmolarity, and particle size of microemulsion propofol are 7.5, 280 mOsm/l, and 67.0 +/- 28.5 nm, respectively. The aqueous free propofol concentration in microemulsion propofol was 63.3 +/- 1.2 mug/ml. When mixed with human blood, microemulsion propofol did not generate bradykinin in plasma. Although microemulsion propofol had nonlinear pharmacokinetics, a two-compartment model with linear pharmacokinetics best described the time course of the propofol concentration as follows: V1 = 0.143 l/kg, k10 = 0.175 min, k12 = 0.126 min, k21 = 0.043 min. The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min. CONCLUSIONS: Microemulsion propofol produced a high concentration of free propofol in the aqueous phase. For the applied dose range, microemulsion propofol showed nonlinear pharmacokinetics.
机译:背景:一种新开发的微乳液丙泊酚由10%纯化的泊洛沙姆188和0.7%聚乙二醇660羟基硬脂酸酯组成。作者研究了理化特性,含水游离异丙酚浓度和血浆缓激肽的产生。还评估了大鼠的药代动力学和药效学。方法:分别使用pH计,粒度分析仪和低温渗透压计测量微乳丙泊酚的pH值,粒径和摩尔渗透压浓度。游离丙泊酚水溶液和血浆缓激肽分别通过透析法和放射免疫法测定。微乳丙泊酚通过0.5、1.0和1.5 mg的零级输注给药。公斤 。 30分钟内,每分钟20分钟。脑电图近似熵用作异丙酚作用的替代量度。结果:微乳丙泊酚的pH值,摩尔渗透压浓度和粒径分别为7.5、280 mOsm / l和67.0 +/- 28.5 nm。微乳液丙泊酚中的游离丙泊酚水溶液浓度为63.3 +/- 1.2杯/毫升。当与人血混合时,微乳液丙泊酚在血浆中不会产生缓激肽。尽管微乳液丙泊酚具有非线性药代动力学,但具有线性药代动力学的两室模型最能描述丙泊酚浓度的时间过程如下:V1 = 0.143 l / kg,k10 = 0.175 min,k12 = 0.126 min,k21 = 0.043 min。乙状结肠Emax模型中的药效学参数如下:E0 = 1.18,Emax = 0.636,Ce50 = 1.87杯/毫升,γ= 1.28,ke0 = 1.02分钟。结论:微乳液丙泊酚在水相中产生高浓度的游离丙泊酚。在应用剂量范围内,微乳丙泊酚显示出非线性的药代动力学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号